C

CSL

Develops and delivers biotherapies and vaccines

GVP Auditor

Full-Time
No salary listed
Mid
Bachelor's
King of Prussia, PA, USA+3 moreMore locations: Kankakee, IL, USA | Boca Raton, FL, USA | Waltham, MA, USA
In PersonThe role requires up to 50% travel.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Bachelor of Science degree in a relevant biological science, pharmacy, or related science discipline.
  • Quality Assurance experience within a Good Pharmacovigilance Practices-regulated environment, with a strong understanding of drug safety operations and regulatory frameworks.
  • Experience in audit and inspection management, with a clear understanding of quality assurance requirements in the pharmacovigilance discipline.
  • Working knowledge of ICH E2D(R1), E2A, E2B(R3), E2C(R2), and E2F guidelines.
  • Working knowledge of 21 CFR Part 314.80 for drugs, 21 CFR Part 600 Subpart D for biologics, and 21 CFR Part 4 for combination products and duplicate reporting prevention.
  • Working knowledge of Directive 2001/83/EC, as amended; Regulation (EC) No 726/2004; Commission Implementing Regulation (EU) No 520/2012; and EMA Good Pharmacovigilance Practices Modules I–XVI and product/population-specific modules.
  • Strong analytical and problem-solving skills, the ability to work with limited supervision, and the ability to manage a schedule involving up to 50% travel.
Responsibilities
  • Conduct assigned external audits of pharmacovigilance vendors and service providers, as well as internal self-inspections of safety processes, systems, and affiliates, including Local and Regional Safety Officer activities.
  • Develop and issue comprehensive audit reports, categorize findings by risk level, and provide recommendations for corrective and preventive actions related to drug safety.
  • Identify non-compliance trends and systematic risks within the pharmacovigilance discipline, and communicate findings to line management and functional leads to support pharmacovigilance system health and protect the integrity of the Pharmacovigilance System Master File.
  • Support initiatives to improve standard operating procedures for audit conduct.
  • Partner with stakeholders to develop risk-based, compliant solutions that ensure compliance with EMA Good Pharmacovigilance Practices guidelines and applicable global and local regulatory requirements.
  • Maintain up-to-date knowledge of global Good Pharmacovigilance Practices regulations and industry trends to support internal quality and compliance.
Desired Qualifications
  • Excellent interpersonal and negotiation skills, with the ability to work effectively with multinational teams and external stakeholders across different regions.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.

Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.